N-methyl-2-methyl-1-piperidinepropanamine | 85723-73-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-methyl-2-methyl-1-piperidinepropanamine
• 英文别名: N,2-Dimethyl-1-piperidinepropanamine；N-methyl-3-(2-methylpiperidin-1-yl)propan-1-amine
• CAS: 85723-73-5
• 化学式: C₁₀H₂₂N₂
• mdl: MFCD11152318
• 分子量: 170.298
• InChiKey: WUTBICCRPDMBRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-溴-N-[4-(2-氟苯甲酰)-1,3-二甲基-1H-吡唑-5-基]-乙酰胺 、 N-methyl-2-methyl-1-piperidinepropanamine 生成 (Z)-but-2-enedioic acid;N-[4-(2-fluorobenzoyl)-2,5-dimethylpyrazol-3-yl]-2-[methyl-[3-(2-methylpiperidin-1-yl)propyl]amino]acetamide
  参考文献：
  名称：

  WISE L. D.; BUTLER D. E.; DEWALD H. A.; LUSTGARTEN D.; COUGHENOUR L. L.; +, J. MED. CHEM., 29,(1986) N 9, 1628-1637

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS AND/OR HEMATOPOIETIC PROGENITOR CELLS<br/>[FR] COMPOSÉS ET LEUR UTILISATION DANS L'EXPANSION DE CELLULES SOUCHES HÉMATOPOÏÉTIQUES ET/OU CELLULES PROGÉNITRICES HÉMATOPOÏÉTIQUES
  申请人：UNIV MONTREAL

  公开号：WO2015161373A1

  公开（公告）日：2015-10-29

  Compounds of general formula or salts or prodrugs thereof, are provided and described herein. The compounds are useful to expand hematopoietic stem cell and/or hematopoietic progenitor cell populations. Particularly, the hematopoietic cells are human cells. The compounds are also useful in the medical treatment of hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immune-deficient disease in a subject.

  本文提供并描述了一般式化合物、盐或其前药。这些化合物对于扩增造血干细胞和/或造血祖细胞群体是有用的。特别地，这些造血细胞是人类细胞。这些化合物还可用于治疗受试者的造血障碍/恶性肿瘤、自身免疫疾病和/或遗传性免疫缺陷疾病。
• DISUBSTITUTED UREAS AS KINASE INHIBITORS
  申请人：Furet Pascal

  公开号：US20090131437A1

  公开（公告）日：2009-05-21

  The invention relates to compounds of the formula (I), their use as kinase inhibitors, new pharmaceutical formulations comprising said compounds, said compounds for use in the diagnostic or therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of diseases or for the manufacture of pharmaceutical formulations useful in the treatment of diseases that respond to modulation of kinase activity, methods of treatment comprising administration of said compounds to a warm-blooded animal, especially a human, and processes for the manufacture of said compounds.

  该发明涉及式(I)的化合物，其作为激酶抑制剂的用途，包括所述化合物的新药物配方，所述化合物用于诊断或治疗温血动物，特别是人类，其用于治疗疾病或用于制造对激酶活性调节产生反应的疾病治疗药物配方的用途，包括将所述化合物用于治疗温血动物，特别是人类的治疗方法，以及所述化合物的制造方法。
• Indenoisoquinolinone analogs and methods of use thereof
  申请人：Jagtap Prakash

  公开号：US20070049555A1

  公开（公告）日：2007-03-01

  The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.

  本发明涉及Indenoisoquinolinone类似物，包括有效量的Indenoisoquinolinone类似物的组合物，以及用于治疗或预防炎症性疾病、再灌注损伤、糖尿病、糖尿病并发症、器官移植引起的再氧化损伤、缺血状况、神经退行性疾病、肾功能衰竭、血管疾病、心血管疾病、癌症、早产并发症、心肌病、视网膜病、肾病、神经病、勃起功能障碍或尿失禁的方法，包括向需要治疗的受体内给予有效量的Indenoisoquinolinone类似物。
• (5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones. A series of novel potential antipsychotic agents
  作者：Lawrence D. Wise、Donald E. Butler、Horace A. DeWald、David Lustgarten、Linda L. Coughenour、David A. Downs、Thomas G. Heffner、Thomas A. Pugsley

  DOI：10.1021/jm00159a011

  日期：1986.9

  (5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanone (1) was found to have an antipsychotic-like profile in behavioral tests predictive of antipsychotic efficacy but, unlike available antipsychotic agents, did not bind in vitro to dopamine receptors. Upon further evaluation, 1 was found to cause clonic seizures in aged rodents. An examination of related structures revealed that 5-(substituted aminoacetamide) analogues of 1 shared this novel pharmacology and did not cause seizures. The synthesis and pharmacological evaluation of this series of compounds are described. Two compounds, 2-(diethylamino)acetamide (25) and 2-[[3-(2-methyl-1-piperidinyl)propyl]-amino]acetamide (38), were selected for examination in secondary tests. Like known antipsychotics both compounds reduced spontaneous locomotion in mice at doses that did not cause ataxia and inhibited conditioned avoidance selectively in both rats and monkeys. Unlike known antipsychotics neither 25 nor 38 elicited dystonic movements in haloperidol-sensitized cebus monkeys, a primate model of antipsychotic-induced extrapyramidal side effects. Biochemical studies indicated that these compounds act via a nondopaminergic mechanism. Neither 25 nor 38 bound to dopamine receptors in vitro or caused changes in striatal dopamine metabolism in vivo. In addition, they did not raise serum prolactin levels as do known antipsychotics. Although adverse animal toxicological findings have precluded clinical evaluation of these agents, the present results indicate that it is possible to identify at the preclinical level nondopaminergic compounds with antipsychotic-like properties.

  (5-氨基-1,3-二甲基-1H-吡唑-4-基)(2-氟苯基)甲酮(1)在预测抗精神病药物效力的行为测试中被发现具有抗精神病样特性,但它与现有的抗精神病药物不同,体外不与多巴胺受体结合。在进一步的评估中,发现1会导致老年啮齿类动物出现阵挛性癫痫。对相关结构的分析表明,1的5-(取代氨基乙酰胺)类似物具有这种新颖的药理学特性,但不会引起癫痫。文中描述了这一系列化合物的合成和药理学评价。两种化合物,2-(二乙基氨基)乙酰胺(25)和2-[[3-(2-甲基-1-吡咯烷基)丙基]氨基]乙酰胺(38),被选中进行次级测试。与已知的抗精神病药物一样,这两种化合物在不引起共济失调的情况下,降低了小鼠的自发运动,并在大鼠和猴子中选择性抑制了条件回避反应。与已知的抗精神病药物不同,25和38都不会引起氯丙嗪敏感的卷尾猴的迟发性运动障碍,这是一种模拟抗精神病药物引起的锥体外系副作用的灵长类动物模型。生化研究表明,这些化合物通过非多巴胺能机制发挥作用。25和38在体外均不与多巴胺受体结合,也不会改变纹状体中多巴胺的代谢,并且与已知的抗精神病药物不同,它们不会升高血清催乳素水平。尽管不良的动物毒理学结果排除了这些药物的临床评估,但目前的结果表明,在临床前阶段有可能发现具有抗精神病样特性的非多巴胺能化合物。
• [EN] SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE SULFONAMIDE EN TANT QU'ANTAGONISTES DU RECEPTEUR DE 5HT7
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO1997029097A1

  公开（公告）日：1997-08-14

  (EN) The invention relates to compounds having 5HT7 antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.(FR) L'invention concerne des composés présentant une activité d'antagonistes de 5HT7, des procédés servant à les préparer, des compositions les contenant, ainsi que leur utilisation dans le traitement de maladies du système nerveux central et d'autres maladies.

  该发明涉及具有5HT7拮抗活性的化合物，其制备过程，含有它们的组合物以及它们在治疗中枢神经系统和其他疾病中的应用。